About Cushing's Syndrome
Cushing's syndrome is a condition caused by the prolonged exposure to very high levels of cortisol. This can occur because of the consumption of glucocorticoid drugs or diseases that result in excess cortisol, ACTH, and CRH secretion. Harvey Cushing described the pathophysiology of this condition in 1932. It is more common in women than in men. Cushing's syndrome is also known as hypercortisolism, hypercorticism, hyperadrenocorticism, or Itsenko-Cushing syndrome. Some of the common symptoms of Cushing's syndrome are increase in weight, facial acne, cognitive disorders, and vulnerability to superficial fungus infections, growth of a mass around the collarbone or back of the neck, commonly known as the "buffalo hump," and puffy face or "moon face". Other symptoms include sweating, polyuria, and hypertension, dilation of the capillaries, thinning of the skin, red striae, osteoporosis, diabetes mellitus, immune suppression, sleep disturbances, muscle weakness, hirsutism, baldness, and hypocalcemia. Cushing's syndrome can broadly be classified into corticotropin-dependent Cushing's syndrome and corticotropin-independent Cushing's syndrome.
TechNavio's analysts forecast the Global Cushing's Syndrome Therapeutics market to grow at a CAGR of 9.41 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Cushing's Syndrome Therapeutics market for the period 2014-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used in the treatment of Cushing's syndrome caused in humans.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Cushing's Syndrome Therapeutics market. In addition, the report discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio's report, the Global Cushing's Syndrome Therapeutics market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global BI and Analytics Platform market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Corcept Therapeutics
• HRA Pharma
• Novartis
Other Prominent Vendors
• Aspireo Pharmaceuticals
• Cortendo
• ElexoPharm
• Ipsen
• Isis Pharmaceuticals
• Orphagen Pharmaceuticals
• Samaritan Pharmaceuticals
Market Driver
• Presence of Unmet Need
• For a full, detailed list, view our report
Market Challenge
• Adverse Effects of Drugs
• For a full, detailed list, view our report
Market Trend
• Increase in Awareness
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Signifor
04.1.2 Korlym
04.1.3 Ketoconazole HRA
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disease Overview
07.1.1 Understanding the Disease
07.1.2 Etiology and Pathophysiology
07.1.3 Rate of Incidence and Prevalence
07.1.4 Diagnosis of Cushing's Syndrome
07.1.5 Management of Cushing's Syndrome
07.1.6 Economic Burden due to Cushing's Syndrome
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Class of Drugs
09.1 Glucocorticoid Receptor Antagonist
09.2 Somatostatin Analog
09.3 Cortisol Synthesis Inhibitor
09.4 Others
10. Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral
11. Market Segmentation by Dosage Form
11.1 Solid
11.2 Liquid
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Novartis
20.2.2 Corcept Therapeutics
20.2.3 HRA Pharma
20.3 Other Prominent Vendors
21. Pipeline Portfolio
21.1 Key Information for the Pipeline Candidates
21.1.1 LCI-699
21.1.2 COR-003
21.1.3 Cabergoline
21.1.4 ISIS-GCCRRx
21.1.5 DG-3173
22. Key Vendor Analysis
22.1 Corcept Therapeutics
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Recent Developments
22.1.4 SWOT Analysis
22.2 HRA Pharma
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Therapeutic Areas
22.2.4 Business Strategy
22.2.5 Recent Developments
22.2.6 SWOT Analysis
22.3 Novartis
22.3.1 Key Facts
22.3.2 Business Description
22.3.3 Business Segmentation
22.3.4 Revenue by Business Segmentation
22.3.5 Revenue Comparison 2012 and 2013
22.3.6 Sales by Geography
22.3.7 Business Strategy
22.3.8 Key Developments
22.3.9 SWOT Analysis
23. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Etiology of Cushing's Syndrome
Exhibit 3: Diagrammatic Representation of Cortisol Secretion and its Feedback Loop
Exhibit 4: Causes of Cushing's Syndrome
Exhibit 5: Diagnosis Algorithm of Cushing's Syndrome
Exhibit 6: Global Overactive Bladder Therapeutics Market 2015-2019 (US$ million)
Exhibit 7: Global Cushing's Syndrome Therapeutics Market Segmentation by Class of Drugs
Exhibit 8: Global Cushing's Syndrome Therapeutics Market by Class of Drugs 2014
Exhibit 9: Global Cushing's Syndrome Therapeutics Market Segmentation by Route of Administration
Exhibit 10: Global Cushing's Syndrome Therapeutics Market by Route of Administration 2014
Exhibit 11: Global Cushing's Syndrome Therapeutics Market Segmentation by Dosage Form
Exhibit 12: Global Cushing's Syndrome Therapeutics Market by Dosage Form 2014
Exhibit 13: Global Overactive Bladder Therapeutics Market by Geographical Segmentation 2014
Exhibit 14: Global Cushing's Syndrome Therapeutics Market Share Analysis 2014
Exhibit 15: Snapshot of Pipeline Drugs 2014
Exhibit 16: Study Count of Cushing's Syndrome Clinical Trials
Exhibit 17: Study Count of Cushing's Syndrome Clinical Trials
Exhibit 18: Novartis AG: Business Segmentation
Exhibit 19: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 20: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 21: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 22: HRA Pharma: Therapeutic Areas
